Boston Scientific Balances Earnings Beat With Cautious Outlook
Boston Scientific ((BSX)) has held its Q2 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Boston Scientific’s latest earnings call conveyed a cautiously optimistic tone, blending strong second-quarter execution with a tougher near-term outlook. Management highlighted a clear beat on earnings, expanding margins, and robust cash generation, yet tempered enthusiasm by cutting guidance amid WATCHMAN weakness and U.S. electrophysiology share losses that are expected to weigh on growth through 2027.
Revenue Beat and Solid Organic Growth
Boston Scientific reported Q2 revenue of $5.442 billion, up 7.5% year over year on a reported basis and 7.0% organically, sitting at the high end of prior guidance. Foreign exchange added roughly 50 basis points to growth, underscoring that the underlying demand environment remains generally healthy despite emerging pockets of softness.
EPS Upside and Margin Expansion
Adjusted EPS came in at $0.86, rising 15% from a year ago and topping the guided range of $0.82 to $0.84, helped by favorable discrete tax items. Profitability also improved, with adjusted gross margin reaching 70.3% and adjusted operating margin expanding to 28.4%, while GAAP operating margin was 21.6% after one-time charges.
Cash Flow Strength and Shareholder Returns
Free cash flow was a standout at $1.29 billion for the quarter, derived from $1.475 billion in operating cash flow and $184 million in capital spending, supporting a full-year free cash flow outlook of about $3.8 billion. The company completed a $2 billion accelerated share repurchase, buying back roughly 40 million shares and ending Q2 with about 1.475 billion diluted shares outstanding.
High-Growth Segments Offset Weaker Franchises
Growth engines across the portfolio continued to deliver, with Neuromodulation up 12%, Interventional Cardiology up 15%, Interventional Oncology and Embolization up 12%, and Vascular/ICVT also advancing 12%. Endoscopy grew 7%, and Asia Pacific posted 11% operational growth, helping counterbalance softness in certain cardiac and urology lines.
Pipeline Progress and Regulatory Wins
The quarter brought several milestones, including U.S. clearance for the RIVOS endoscopy system and TruSelect microcatheter, adding to the company’s minimally invasive toolkit. On the clinical front, the FRACTURE trial for SEISMIQ 4CE hit its endpoints, while renal denervation program TIVUS and the FARADIGM pivotal trial for FARAFLEX continued to advance.
Strategic Deals to Bolster Long-Term Growth
Boston Scientific outlined a $1.5 billion strategic investment in MiRus, gaining an option on transcatheter aortic valve replacement assets that could deepen its structural heart presence. Management also reiterated expectations to close the Penumbra acquisition in the second half of 2026, positioning the company for an expanded neurovascular footprint and a stronger long-term growth profile.
Restructuring Aimed at Efficiency and Margins
To fund priority investments while preserving profitability, the company launched a broad restructuring program targeting about $500 million in annualized savings exiting 2029. More than half of those savings are expected to be realized by the end of 2027, with management framing the effort as a key lever for margin expansion from 2028 onward.
Guidance Reset Highlights Near-Term Revenue Pressure
Full-year 2026 guidance was tightened to 5% to 6% organic revenue growth, implying reported growth of 5.5% to 6.5% with a modest FX tailwind and a softer second half. Q3 organic growth is now seen at 3% to 5%, while full-year adjusted EPS is pegged at $3.28 to $3.32, equivalent to 7% to 8% growth and signaling a more challenging operating backdrop.
WATCHMAN Growth Stalls Amid Market Shift
WATCHMAN, a key left atrial appendage closure franchise, slowed sharply to 4% growth in Q2, with international markets up 18% but the U.S. only 3%, as stand-alone procedures fell by low-teens percentages. Management now expects WATCHMAN sales to be flat to low-single digits for 2026, with second-half revenue declining mid- to high-single digits and no improvement assumed in stand-alone procedures next year.
Electrophysiology Faces U.S. Share Pressure
Electrophysiology sales increased 9% overall, driven by 23% growth internationally, but U.S. sales grew only 3% amid unexpected competitive share losses. As a result, the company cut its outlook, guiding global EP growth to roughly flat in the back half of 2026 and forecasting U.S. EP growth at flat to low-single digits for the full year.
CRM and Urology Weaken as Gaps Emerge
Cardiac Rhythm Management revenue slipped 2% in the quarter, with low-voltage devices down high-single digits and high-voltage down mid-single digits, reflecting portfolio gaps in a crowded market. Urology grew just 1% and is now expected to be flat to low-single digits for the year, with management pointing to slower recovery in sacral neuromodulation and product gaps in stone management.
Margin Mix Pressures and Penumbra Dilution
Despite near-term operating margin expansion, the company warned that full-year adjusted gross margin will trail 2025 levels due to weaker mix from WATCHMAN and EP and continued investments. The pending Penumbra acquisition is expected to be slightly dilutive to operating margins and EPS in 2026, adding to the pressure before benefits from integration and restructuring flow through.
Limited EPS Growth Expected in 2027
Boston Scientific flagged 2027 as a transition year, projecting little room for adjusted EPS growth as WATCHMAN and EP softness persists and mix-driven gross margin pressure lingers. Early integration impacts from the Penumbra deal are also expected to weigh on results, limiting operating leverage even as cost savings programs ramp in the background.
One-Time Items and FX Volatility
Results included roughly $75 million in product liability charges and about $80 million in tariff refunds, adding noise to reported earnings but not altering the underlying trend. Adjusted interest and other expense of about $120 million came in slightly unfavorable, and foreign exchange is projected to be a roughly $0.05 headwind to full-year adjusted EPS.
WATCHMAN Uncertainty and Evolving Clinical Landscape
Management emphasized that evolving clinical data from recent trials has significantly altered referral patterns for left atrial appendage closure, adding uncertainty to WATCHMAN adoption. Potential new competitors and reimbursement shifts could further pressure the franchise in 2027, and the company is not yet embedding a rebound in its planning assumptions.
Forward Guidance and Outlook
Looking ahead, Boston Scientific expects 2026 organic growth of 5% to 6% and Q3 organic growth of 3% to 5%, with Q3 adjusted EPS in the $0.80 to $0.82 range and a full-year EPS increase of 7% to 8%. Management is targeting modest operating margin expansion of up to 25 basis points in 2026, supported by robust free cash flow of about $3.8 billion, while planning around flat EP in the second half and declining WATCHMAN volumes.
Boston Scientific’s earnings call painted a company executing well operationally but bracing for a more volatile demand environment in key cardiac franchises. Investors are being asked to look through a choppy 2026 and a constrained 2027, with management betting that restructuring, strategic deals, and a deep pipeline will reset the growth trajectory and margins as the company moves toward 2028 and beyond.
